Abstract
Previously we observed that the antiestrogens tamoxifen and 4-hydroxytamoxifen (4OHT) induce CYP3A4 in primary human hepatocytes and activate human pregnane X receptor (PXR) in cell-based reporter assays. Given the complex cross-talk between nuclear receptors, tissue-specific expression of CYP3A4, and the potential for tamoxifen and 4OHT to interact with a myriad of receptors, this study was undertaken to gain mechanistic insights into the inductive effects of tamoxifen and 4OHT. First, we observed that transfection of the primary cultures of human hepatocytes with PXR-specific small interfering RNA reduced the PXR mRNA expression and the extent of CYP3A4 induction by tamoxifen and 4OHT by 50%. Second, in LS174T colon carcinoma cells, which were observed to have significantly lower PXR expression relative to human hepatocytes, neither tamoxifen nor 4OHT induced CYP3A4. Third, N-desmethyltamoxifen, which did not induce CYP3A4 in human hepatocytes, also did not activate PXR in LS174T cells. We then used cell-based reporter assay to evaluate the effects of other receptors such as glucocorticoid receptor GRα and estrogen receptor ERα on the transcriptional activation of PXR. The cotransfection of GRα in LS174T cells augmented PXR activation by tamoxifen and 4OHT. On the other hand, the presence of ERα inhibited PXR-mediated basal activation of CYP3A4 promoter, possibly via competing for common cofactors such as steroid receptor coactivator 1 and glucocorticoid receptor interacting protein 1. Collectively, our findings suggest that the CYP3A4 induction by tamoxifen and 4OHT is primarily mediated by PXR but the overall stoichiometry of other nuclear receptors and transcription cofactors also contributes to the extent of the inductive effect.
Footnotes
-
This study was supported in part by a grant from the American Cancer Society (Ohio Division) (P.B.D.) and a predoctoral fellowship (R.S.S.) from the Susan G. Komen for the Cure foundation.
-
No official support or endorsement of this article by the Food and Drug Administration is intended or should be inferred.
-
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
-
doi:10.1124/dmd.107.018598.
-
ABBREVIATIONS: NDMT, N-desmethyltamoxifen; 4OHT, 4-hydroxytamoxifen; PXR, pregnane X receptor; GR, glucocorticoid receptor; HNF, hepatic nuclear factor; ER, estrogen receptor; siRNA, small interfering RNA; XREM, xenobiotic response element module; SRC1, steroid receptor coactivator 1; GRIP1, glucocorticoid receptor interacting protein 1; ERE, estrogen receptor response element; PCR, polymerase chain reaction; RXR, retinoid X receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; BSA, bovine serum albumin; ANOVA, analysis of variance; CAR, constitutive androstane receptor.
-
↵1 Current affiliation: Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT.
-
↵2 Current affiliation: Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
- Received September 3, 2007.
- Accepted February 15, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|